滤泡性淋巴瘤

滤泡性淋巴瘤与反应性淋巴滤泡增生的免疫组化及DNA图像分析研究

Immunohistochemical and DNA image cytometric study of follicular lymphoma and reactive follicular hyperplasia

Castleman′s病与滤泡性淋巴瘤的免疫组化研究

Immunohistochemistry analysis in Castleman disease and follicular lymphoma

结果4例均为B细胞淋巴瘤，其中3例为弥漫型滤泡性淋巴瘤，1例为伯基特淋巴瘤；

Results Four cases were B-cell lymphomas : one non-endemic Burkitt 's lymphoma and three follicular lymphomas ;

bcl-2癌基因蛋白在滤泡性淋巴瘤中的表达及意义

Expression and significance of bcl-2 oncogene protein in follicular lymphoma and lymphoid follicular hyperplasia

结论：Bcl－2的免疫组化检测是鉴别淋巴结反应性增生与滤泡性淋巴瘤较可靠的诊断方法。

Conclusions The immunohistochemical detection of Bcl 2 may be used to differentiate follicular lymphoma from reactive hyperplasia in lymph node .

结果：（1）宫颈鳞癌、卵巢常见恶性肿瘤（浆液性及粘液性囊腺癌）、滤泡性淋巴瘤的DNA含量和超二倍体率均显著高于相应起源组织或良性肿瘤；

Results : ( 1 ) DNA contents and the ratio of hyperdiploid were higher in cervical squamous carcinoma , serous and mucinous ovarian cystadenocarcinoma and follicular lymphoma than those of their corresponding original tissues or benign lesions .

50%～80%的滤泡性淋巴瘤，10%～25%的弥漫性大细胞性B细胞淋巴瘤中有Bcl2蛋白的表达。

Bcl 2 protein was expressed in 50 % - 80 % of follicular lymphomas 、 10 % - 25 % of diffuse large B cell lymphomas .

除了代表潜在的生物标记物外，伴有缺陷BCR信号的细胞存在可提供滤泡性淋巴瘤新的靶点。

In addition to representing a potential biomarker , the existence of cells with defective BCR signaling may provide new targets against follicular lymphoma . & JCL .

目的：探讨Castleman′s病与滤泡性淋巴瘤的鉴别诊断方法。

Objective : To study a method to distinguish Castleman ′ s disease ( CD ) from follicular lymphoma ( FL ) .

结果显示，20例滤泡性淋巴瘤中，15例bcl2阳性。5例bcl2阴性；

The results showed that bcl - 2 was positive in 15 and negative in 5 of 20 Fls , but negative in 8 and weakly positive in 2 of the FHs .

结果17例RLH生发中心细胞、10例滤泡性淋巴瘤（FL）及4例弥漫性大B细胞淋巴瘤（DLBCL）中等强度表达BCL-6；

RESULTS BCL 6 was expressed moderately in cells within the germinal center of the 17 cases of RLH , in 10 cases of follicular lymphoma ( FL ) and in 4 cases of diffuse large B cell lymphoma ( DLBCL ) .

91%的滤泡性淋巴瘤（Fls）中可发现染色体t（14；18）（q32；q21）-IgH/Bcl-2。

It can suppress apoptosis at normal . Chromosome t ( 14 ; 18 ) ( q32 ; q21 ) - IgH / Bcl-2 can be detected in about 91 % of Fls .

滤泡性淋巴瘤内免疫球蛋白沉着免疫组化与电镜研究

Immunoglobulin deposists in follicular lymphomas : Immunohistochemical and ultrastructural studies

伴浆细胞分化的滤泡性淋巴瘤临床病理分析

Follicular lymphoma with plasmacytic differentiation : a clinicopathologic analysis

如果你的滤泡性淋巴瘤治疗后复发（复发性）或对初始治疗无效（难治性），你将接受二线治疗。

If your follicular lymphoma returns after treatment ( recurrence ) or does not respond to initial treatment ( refractory ), you will be given second-line therapy .

结论中国浙江地区汉族人群中低的BCL-2/IgH易位率可能是滤泡性淋巴瘤发病率较欧美国家低的原因之一。

Conclusion The low frequency of BCL-2 / IgH translocation in healthy Chinese individuals of Han nationality located in Zhejiang area may be one of the reasons for the difference in the incidence of FL between China and Western countries .

结果表明：13例滤泡中心性淋巴瘤bcl-2蛋白阳性，1例淋巴浆细胞淋巴瘤bcl－2蛋白阳性，总阳性率77.8%。

The results showed that 13 lymphomas of the follicular centrocytes were usually the most strongly labeled and 1 lymphoplasmacytic lymphoma was positive . 77 . 8 % of cases were positive .

滤泡性B细胞淋巴瘤是一种非霍奇金淋巴瘤，肿瘤疫苗是治疗是根据肿瘤细胞的生物学特殊性。

The cancer vaccines rely on a biological quirk of follicular B-cell lymphoma , which is a type of non-Hodgkin 's lymphoma .

结论：bcl6可作为滤泡中心细胞性淋巴瘤的特异标志而区别于其他类型小B细胞淋巴瘤；

Conclusions bcl 6 may be a useful marker for identifying FL from other small B cell lymphomas .

结论在扁桃体的正常滤泡内与滤泡性淋巴瘤的肿瘤性滤泡内T细胞处于G0期，胃MALT淋巴瘤中肿瘤性B细胞的增生可能依赖于Hp特异性的T细胞。

Proliferation of neoplastic B cells in low grade gastric MALT type lymphomas requires Hp specific infiltrating T cells .

淋巴滤泡瘤样增生与滤泡性淋巴瘤鉴别诊断高碘甲状腺肿是由于滤泡扩张，过多胶质堆积在滤胞腔内所致，并非TSH升高导致甲状腺滤泡增生的结果。

Differential diagnosis between follicular lymphoma and tumor-like follicular hyperplasia Iodide goiter was not due to elevation of TSH level to induce the thyroid follicular hyperplasia .